TIDREC
30.6.2020 16:59:14 CEST | Business Wire | Press release
Laboratory testing completed at the Tropical Infectious Diseases Research and Education Center (TIDREC) at the University of Malaya, Malaysia, has confirmed the effectiveness of BETADINE® Gargle and Mouthwash against the novel coronavirus (SARS-CoV-2) which causes COVID-19 disease. BETADINE® is manufactured and distributed in Malaysia by Mundipharma.
BETADINE® Gargle and Mouthwash was tested for virucidal activity in two concentrations, undiluted (PVP-I 1% w/v) and at a 1:2 dilution (PVP-I 0.5% w/v) under established European (EN14476) methodology and standards. The testing demonstrated strong in-vitro virucidal activity, with the tested products killing 99.99% of the SARS-CoV-2 virus in just 15 seconds.
The TIDREC research has been accepted by the British Dental Journal (BDJ) and was published as a Letter on 26 June 2020. The journal is published by Springer Nature on behalf of the British Dental Association.
“Laboratory testing has shown that BETADINE® Gargle and Mouthwash is effective against COVID-19 and could contribute to our ongoing efforts to keep people and communities safe,” said Dr Pouya Hassandarvish, the Lead Investigator of the Study and the postdoctoral fellow researcher at TIDREC, University of Malaya.
“These results confirm our view that BETADINE® Gargle and Mouthwash, used appropriately and in conjunction with other preventative treatment options including PPE, could play a role in limiting the spread of infections, including COVID-19,” said Raman Singh, Mundipharma CEO.
“It also provides the medical and dental community with a science-based assurance that they are using a product that is specifically studied against COVID-19,” he added.
Previously, BETADINE® antiseptic products containing Povidone-iodine (PVP-I) have been proven effective against a wide range of viruses, including coronaviruses that have caused major outbreaks such as Middle East Respiratory Syndrome (MERS) and Severe Acute Respiratory Syndrome (SARS). The BETADINE® antiseptic range contains Povidone-iodine (PVP-I), which is effective against a wide range of microorganisms, including bacteria, viruses and fungi and is typically used in hospitals and homes.
About TIDREC
TIDREC serves as a focal point for national and international collaborative research for academic institutions and research industries in Malaysia. TIDREC also emphasizes on education and development of human skills. By advocating safe laboratory science, TIDREC aspires to be an internationally recognized centre of excellence in tropical infectious diseases research and education that serves the health needs of global communities.
TIDREC was the first research centre in the country to install fully certified modular biosafety level 2 & 3 laboratories for research involving highly virulent pathogens. TIDREC is also the only centre currently operating a mock biosafety level 3 training facility. The centre also houses the WHO Collaborating Centre for Arbovirus Reference & Research. The centre offer services such as drug screening, validation test for diagnostic kits and research collaboration on vector-borne diseases.
TIDREC mission is to advance knowledge by focusing on research in neglected tropical infectious diseases that have a potential impact on the global community.
About Mundipharma
Mundipharma’s independent associated companies are privately owned entities covering the world’s pharmaceutical markets. Mundipharma is a prime example of a company that consistently delivers high-quality products while standing by the values that represent the company. Our mission is to alleviate the suffering of patients with cancer and non-cancer pain and to substantially improve their quality of life. Mundipharma is dedicated to bringing to patients with severe and debilitating diseases the benefit of novel treatment options in fields such as pain, oncology, oncology supportive care, ophthalmology, respiratory disease and consumer healthcare.
About BETADINE®
The BETADINE® range of products have been trusted by hospitals and consumers around the world for over 60 years to prevent and treat infections. Over the last few years, Mundipharma has expanded the BETADINE® range of products to include Povidone-iodine and non-povidone iodine ranges for the prevention, treatment and maintenance of a range of conditions from upper respiratory tract infections, wound infections, feminine hygiene and infections and outbreaks to personal and hand hygiene. In-vitro and clinical studies have demonstrated that BETADINE® Povidone-iodine kills a broad range of bacteria, viruses and fungi including antibiotic-resistant strains.
®: BETADINE is a registered trademark of Mundipharma
View source version on businesswire.com: https://www.businesswire.com/news/home/20200630005731/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mindbreeze InSpire Reduces Token Maxxing, Turning Runaway AI Costs Into Predictable Enterprise Value28.7.2026 15:03:00 CEST | Press release
By grounding generative AI in precise, governed enterprise knowledge, Mindbreeze InSpire cuts the wasted tokens that inflate AI budgets and erode answer quality. Mindbreeze, a leading global provider of AI-based knowledge management solutions, today announced that Mindbreeze InSpire reduces token maxxing, the costly overconsumption of large language model (LLM) tokens that is straining enterprise AI budgets. By retrieving only the most relevant, grounded content and passing it to LLMs with precision, Mindbreeze InSpire lowers the tokens required per answer while improving accuracy, giving enterprises a path to scalable AI with predictable economics. Token maxxing has become one of the most underestimated risks in enterprise AI. As organizations connect generative AI to their data, many default to injecting large volumes of undifferentiated context into every prompt, repeatedly, across thousands of queries. Industry analysis has warned that tokens are becoming the true unit of AI cost,
Uptime Institute 16th Annual 2026 Global Data Center Survey: Deployment of High Density Racks Rising Fast, Operators Face Continued Recruiting and Retention Pressures28.7.2026 15:02:00 CEST | Press release
Uptime Institute today released the findings of its 16th Annual Global Data Center Survey, the most comprehensive study of the digital infrastructure sector. The 2026 results reveal an industry navigating workforce constraints, escalating outage expenses, even as rising costs remain the top concern for management teams. Financial Pressure and Resource Constraints Intensify: While high costs continue to be a primary concern for data center leaders, the 2026 survey also highlights escalating concerns over capacity forecasting, power availability, and supply chain disruptions. Power efficiency gains remain gradual. The industry saw minor improvements in average Power Usage Effectiveness (PUE) levels this year. While newer facilities may boast highly efficient designs, overall global progress is slowed by legacy infrastructure. The AI and Density Reality Check: Despite market enthusiasm for Artificial Intelligence, expectations for AI in data center operations cooled slightly in 2026. Oper
Torq Unveils the SOC Brain: The AI SOC That Learns, Not Just Remembers28.7.2026 15:00:00 CEST | Press release
New Torq AI SOC Platform layer’s innovative capabilities learn from every security decision and historical incident, drawing conclusions from precedents and team judgments from day zero Torq, the established agentic security operations leader, today introduced Torq SOC Brain™, a new layer of the Torq AI SOC Platform that continuously learns from historical investigations, analyst decisions, and organization-specific security operations to create a unified, self-learning AI SOC. While most autonomous investigation systems claim to be self-learning, they are, in reality, memory systems—they simply retrieve past cases and pass them to a language model at decision time. Torq SOC Brain is fundamentally different. It reasons from precedent, adapts to how each SOC evaluates risk, and continuously refines its judgment with every completed investigation. The result is an AI SOC that grows more accurate over time—not a thin wrapper around a generic AI model. This press release features multimedi
AUTOBACS SEVEN Marks 10 Years of System Stability and Self-Funded Innovation with Rimini Street28.7.2026 15:00:00 CEST | Press release
Japan’s leading automotive aftermarket retailer uses Rimini Smart Path™ to accelerate innovation without disrupting its core SAP ECC and Oracle Database systems Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that AUTOBACS SEVEN Co., Ltd. celebrates its 10-year partnership with Rimini Street, marking a decade of stable core operations and reinvestment in innovation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260728266493/en/ AUTOBACS SEVEN Marks 10 Years of System Stability and Self-Funded Innovation with Rimini Street Since switching to Rimini Support™ for SAP ECC 6 in 2016, AUTOBACS SEVEN has expanded its partnership to include Oracle Database, helping the company stabilize mission-critical systems, reduce maintenance burden and free resources for innovation. “At AUTOBACS SEVEN, our lea
Abnormal AI Extends its Behavioral Security Platform to Identity and AI Security28.7.2026 15:00:00 CEST | Press release
Abnormal launches three new products: Identity Threat Protection, AI Governance, and Infiltration Prevention to secure the modern identity attack surface Abnormal AI, the AI-native behavior security company trusted by more than 25% of the Fortune 5001, today announced the expansion of its Behavioral Security Platform across the enterprise, introducing three new products: Identity Threat Protection, AI Governance, and Infiltration Prevention. Together, the launch extends the behavioral AI that already secures over 4,500 customers1 to the identities, AI systems and onboarding pipeline that attackers increasingly exploit. Additionally, customers can now activate products from the AI App Store, a new interface to turn on Abnormal products in a single click. For nearly a decade, Abnormal has protected organizations by understanding behavior, learning what normal looks like for every identity and detecting the deviations that signal anomalous activity or an attack. That behavioral foundation
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom